Latest news with #CorFlow
AFP
06-05-2025
- Business
- AFP
CorFlow Therapeutics Appoints Chris O'Connell as Chairman of the Board of Directors
CorFlow Therapeutics AG (CorFlow) is pleased to announce the appointment of Chris O'Connell as Chairman of the Board of Directors, replacing Rick Geoffrion who remains as a Director on the Board. Chris is a highly regarded senior executive, board member and advisor across the medical devices, life sciences and global healthcare industries. Chris built his career over 21 years at Medtronic (MDT) serving in multiple business areas and functions during an era of rapid expansion. This included senior leadership roles in the Cardiovascular and Diabetes business units, before becoming Executive Vice President and President of the Restorative Therapies Group. Chris was a member of the Medtronic Executive Committee for nine years. Chris later became CEO and President of the Waters Corporation (WAT) which he led to robust business and share price growth for over five years. He currently serves as an Independent Director of innovative growth companies in medical devices, life sciences and diagnostics, as well as several non-profit organizations. This press release features multimedia. View the full release here: Chris O'Connell, Chairman, Board of Directors, CorFlow Paul Mead, CEO of CorFlow, said 'Chris brings exceptional strategic and operational acumen to CorFlow at a pivotal growth phase, where the company can benefit tremendously from his experience. Chris knows exactly how high the bar is set for excellence across all functions in MedTech, both from his corporate and board experiences, and from having been on the buy side of many M&A transactions. On behalf of our board, shareholders, and employees, we're thrilled to have him on board.' Paul added, 'I would like to take this opportunity to extend my sincere gratitude for the personal support and commitment from Rick Geoffrion over the past few years, who I am glad will remain on our Board in an independent capacity.' Chris joins CorFlow as the company embarks on achieving ambitious Series B objectives, which include two parallel clinical trials, an FDA IDE trial to obtain marketing authorization in the United States, and a landmark randomized therapy trial in Europe. CorFlow's technology aims to be the first to both diagnose and deliver therapy for heart attack patients suffering from microvascular obstruction, with a precise system that fits into the existing workflow for interventional cardiologists. The company's first in human MOCA I study results have been presented at the recent TCT and EuroPCR scientific congresses, and preclinical findings at the European Society of Cardiology meeting. CorFlow closed a €44M Series B in late 2024 with an international venture capital syndicate, and recently added further capital for expanded clinical, R&D, and capability advancement. Chris commented, 'I am honored to join the CorFlow team, and highly motivated by the opportunity to help address a major unmet medical need for patients suffering from microvascular obstruction. CorFlow is poised for breakthrough success with such a transformative technology set, talented CEO and team, and experienced investor group. We have all the ingredients to achieve something special.' About CorFlow Therapeutics: Headquartered in Baar, Switzerland. CorFlow aspires to be the leader in diagnostic and therapeutic solutions for restoring healthy microvascular blood flow anywhere in the human body where a critical need exists. Working in close partnership with scientists from the University of Bern, ETH Zurich and the University Hospital Zurich, in a collaboration funded by the Swiss Innovation Agency (Innosuisse), CorFlow continues to explore applications in and beyond the heart. View source version on Media and Scientific Contact CorFlow Therapeutics AG hello@ © Business Wire, Inc. Avertissement : Ce communiqué de presse n'est pas un document produit par l'AFP. L'AFP décline toute responsabilité quant à son contenu. Pour toute question le concernant, veuillez contacter les personnes/entités indiquées dans le corps du communiqué de presse.
Business Wire
06-05-2025
- Business
- Business Wire
CorFlow Therapeutics任命Chris O'Connell為董事會主席
瑞士巴爾--(BUSINESS WIRE)--(美國商業資訊)-- CorFlow Therapeutics AG (CorFlow) 高興地宣布，Chris O'Connell將接替Rick Geoffrion成為董事會主席，後者將繼續擔任董事會董事。Chris是醫療器材、生命科學和全球保健產業備受推崇的高階主管、董事會成員和顧問。Chris曾在Medtronic（MDT）工作了21年，在公司快速擴張時期任職於多個業務領域和職能部門，在成為執行副總裁暨Restorative Therapies Group總裁之前，他曾在心血管和糖尿病業務部門擔任高級領導職務，並曾任Medtronic執行委員會成員長達九年。後來，Chris出任Waters Corporation（WAT）執行長兼總裁，在他的領導下，公司的業務和股價連續五年強勁成長。目前，Chris擔任醫療器材、生命科學和診斷領域創新成長公司以及多家非營利組織的獨立董事。 CorFlow執行長Paul Mead表示：「Chris為處於關鍵發展階段的CorFlow帶來了非凡的策略和營運智慧，他的經驗將使公司受益匪淺。Chris擁有豐富的企業和董事會經驗，並曾在許多併購交易中擔任買方，因此他清楚地瞭解醫療技術領域各職能部門的卓越標準有多高。我代表董事會、股東和員工對他的加入表示熱烈歡迎。」 Paul補充說：「我想藉此機會對Rick Geoffrion在過去幾年中給予我們的個人支援和承諾表示衷心的感謝，我很高興他將以獨立身分繼續留在我們的董事會。」 Chris加入CorFlow之際，公司正著手實現雄心勃勃的B輪融資目標，其中包括兩項平行臨床試驗、一項旨在獲得美國市場銷售授權的FDA IDE試驗和一項在歐洲具有里程碑意義的隨機治療試驗。CorFlow致力於成為首家能夠為微血管阻塞的心臟病患者提供診斷及治療技術的公司，其精確的系統可介入心臟科專家的現有工作流程。該公司的首個人體MOCA I 研究結果已在最近的TCT和EuroPCR科學大會上公布，臨床前研究結果也已在歐洲心臟學會大會上發表。CorFlow在2024年底與一家國際創投財團完成了4,400萬歐元的B輪融資，近期亦追加了更多用於擴大臨床、研發和能力提升的資金。 Chris表示：「我很榮幸能加入CorFlow團隊，有機會幫助微血管阻塞患者解決尚未得到滿足的巨大醫療需求，這對我來說是莫大的激勵。CorFlow的變革性技術、才華橫溢的執行長及其團隊以及經驗豐富的投資者團體將共同推動突破性的成功。我們具備了取得卓越成就的所有要素。」 關於CorFlow Therapeutics： CorFlow總部位於瑞士巴爾，致力於成為在人體任何需要恢復健康微循環血流的部位提供診斷和治療解決方案的領導者。在瑞士創新署（Innosuisse）的資助下，CorFlow與伯恩大學、蘇黎世聯邦理工學院和蘇黎世大學醫院的研究人員密切合作，持續探索心臟及其之外領域的應用。 免責聲明：本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用，煩請參照原文，原文版本乃唯一具法律效力之版本。
National Post
06-05-2025
- Business
- National Post
CorFlow Therapeutics Appoints Chris O'Connell as Chairman of the Board of Directors
Article content BAAR, Switzerland — CorFlow Therapeutics AG (CorFlow) is pleased to announce the appointment of Chris O'Connell as Chairman of the Board of Directors, replacing Rick Geoffrion who remains as a Director on the Board. Chris is a highly regarded senior executive, board member and advisor across the medical devices, life sciences and global healthcare industries. Chris built his career over 21 years at Medtronic (MDT) serving in multiple business areas and functions during an era of rapid expansion. This included senior leadership roles in the Cardiovascular and Diabetes business units, before becoming Executive Vice President and President of the Restorative Therapies Group. Chris was a member of the Medtronic Executive Committee for nine years. Chris later became CEO and President of the Waters Corporation (WAT) which he led to robust business and share price growth for over five years. He currently serves as an Independent Director of innovative growth companies in medical devices, life sciences and diagnostics, as well as several non-profit organizations. Article content Paul Mead, CEO of CorFlow, said 'Chris brings exceptional strategic and operational acumen to CorFlow at a pivotal growth phase, where the company can benefit tremendously from his experience. Chris knows exactly how high the bar is set for excellence across all functions in MedTech, both from his corporate and board experiences, and from having been on the buy side of many M&A transactions. On behalf of our board, shareholders, and employees, we're thrilled to have him on board.' Article content Paul added, 'I would like to take this opportunity to extend my sincere gratitude for the personal support and commitment from Rick Geoffrion over the past few years, who I am glad will remain on our Board in an independent capacity.' Article content Chris joins CorFlow as the company embarks on achieving ambitious Series B objectives, which include two parallel clinical trials, an FDA IDE trial to obtain marketing authorization in the United States, and a landmark randomized therapy trial in Europe. CorFlow's technology aims to be the first to both diagnose and deliver therapy for heart attack patients suffering from microvascular obstruction, with a precise system that fits into the existing workflow for interventional cardiologists. The company's first in human MOCA I study results have been presented at the recent TCT and EuroPCR scientific congresses, and preclinical findings at the European Society of Cardiology meeting. CorFlow closed a €44M Series B in late 2024 with an international venture capital syndicate, and recently added further capital for expanded clinical, R&D, and capability advancement. Article content Chris commented, 'I am honored to join the CorFlow team, and highly motivated by the opportunity to help address a major unmet medical need for patients suffering from microvascular obstruction. CorFlow is poised for breakthrough success with such a transformative technology set, talented CEO and team, and experienced investor group. We have all the ingredients to achieve something special.' Article content About CorFlow Therapeutics: Headquartered in Baar, Switzerland. CorFlow aspires to be the leader in diagnostic and therapeutic solutions for restoring healthy microvascular blood flow anywhere in the human body where a critical need exists. Working in close partnership with scientists from the University of Bern, ETH Zurich and the University Hospital Zurich, in a collaboration funded by the Swiss Innovation Agency (Innosuisse), CorFlow continues to explore applications in and beyond the heart. Article content Article content Article content Article content
